BioCentury | Sep 16, 2020
Deals

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing. Innovent Biologics Inc. (HKSE:1801) has acquired...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
BioCentury | Apr 24, 2019
Clinical News

Gracell reports more potent CD19 CAR T using single-day manufacturing platform

Gracell said its platform was able to manufacture in a single day a CD19-targeting CAR T cell therapy shown to be 20-40 times more potent than conventionally manufactured CAR T therapies in a first-in-human non-IND...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BioCentury | Mar 25, 2019
Distillery Therapeutics

CD19 CAR T cells for lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Mouse studies suggest CD19-targeted CAR T cells could help treat lupus. In two mouse models of lupus, retro-orbital injection of CD19-targeting CAR T cells decreased the number of CD19-positive...
BioCentury | Mar 7, 2019
Preclinical News

Beyond cancer: CAR T cells treat lupus in mice

University of Tennessee researchers have shown that CD19-targeted CAR T cells could help treat lupus, suggesting the approach could be applied to diseases beyond cancer. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by...
BioCentury | Mar 5, 2019
Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting NR4A1, NR4A2 and NR4A3 in CAR T cells could enhance the cells' efficacy in melanoma, colorectal cancer and other solid tumor types. In CD8+...
Items per page:
1 - 10 of 35